Achillion Pharmaceuticals

300 George St, New Haven, CT 06511

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion’s drug discovery pipeline embodies an innovative program-based approach to identifying new infectious disease targets and designing small molecule drugs to attack these targets, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis C viruses (HCV) and the human immunodeficiency virus (HIV) as well as new antimicrobial drugs.

Acorda Therapeutics

15 Skyline Dr, Hawthorne, NY 10532

Acorda Therapeutics is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda’s lead product candidate, Fampridine-SR, is currently in Phase 3 clinical trials for chronic SCI and Phase 2 clinical trials for MS. The Company's clinical-stage pipeline also includes valrocemide, which it is developing with Teva Pharmaceutical Industries Ltd. for the treatment of epilepsy and bipolar disorder. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Acusphere
(ACUS.PK) 0.08

500 Arsenal Street, Watertown, MA 02472

Acusphere is a specialty pharmaceutical company that develops improved formulations of existing drugs and drug delivery systems using its proprietary porous microparticle drug delivery technology. Our current product candidates are designed to address large, unmet clinical needs in the areas of cardiology, oncology and respiratory disease. We have developed a proprietary technology that enables control over the size and porosity of microparticles, thus providing increased flexibility with which to develop drugs that can be delivered via many routes of administration. With this microparticle technology, we have created an intravenous gas delivery system for ultrasound contrast, hydrophobic drug delivery system and a pulmonary drug delivery system.

Aderis Pharmaceuticals

85 Main St, Hopkinton, MA 01748

Aderis Pharmaceuticals was founded in 1994 to develop and commercialize a new generation of pharmaceuticals. Our candidates include selectively-acting, small molecule therapeutics to improve and protect the quality of life for people living with CNS, cardiovascular and renal diseases. Aderis Pharmaceuticals develops its new medicines by targeting the molecular underpinnings of disease with proprietary small-molecule drugs that either mimic (agonists) or oppose (antagonists) the actions of the body's natural signal molecules. Aderis has designed proprietary small molecule analogs of signal molecules that act at individual receptor subtypes. These receptor-subtype selective drugs exert a more potent therapeutic action with fewer side effects than are possible with current standard products, which cannot distinguish among members of a particular receptor family.

AdipoGenix, Inc.

801 Albany Street, Suite 112, Boston, MA 02118

AdipoGenix, Inc. is a Boston-based biopharmaceutical company developing small molecule pharmaceuticals to treat obesity and its co-morbidities.

Adnexus Therapeutics, Inc.

100 Beaver St, Waltham, MA 02453

Adnexus discovers and develops a novel, proprietary class of targeted biologics called Adnectins™. We believe Adnectins possess competitive therapeutic, manufacturing and commercial advantages over traditional targeted therapeutic classes, such as antibodies and small molecules. At Adnexus, we are developing a novel, proprietary drug class that we call Adnectins™, which we believe possess competitive therapeutic, manufacturing and commercial advantages over traditional targeted therapeutic classes, such as antibodies and small molecules. We generate Adnectins by applying PROfusion™, our proprietary protein engineering system. PROfusion allows us to engineer trillions of Adnectin amino acid sequences at a time and to test and identify those sequences that will offer the most attractive drug properties. Together, Adnectins and PROfusion enable design and development of innovative targeted therapeutics.

Advanced Cell Technology

One Innovation Dr, Biotech Three, Worcester, MA 01605

Advanced Cell Technology, Inc. (ACT) is a company engaged in the research and development of technologies enabling the genetic manipulation of cells to produce transgenic animals for pharmaceutical protein production. The Company is also developing transgenic cloned cells and tissues for applications in cell and organ transplant therapy. The Company's initial focus is on the development of cloned transgenic cows to produce human serum albumin and as donors of neural cells for transplant therapies in the treatment of neurodegenerative diseases and diabetes. The Company is also developing transgenic swine for potential application in xenotransplantation. In addition, ACT is advancing technology to produce primitive human embryonic stem cells through nuclear transfer techniques. Using ACT's technology, production of human embryonic stem cells may overcome two major hurdles in the use of transplanted tissue to treat disease. First, the technique may prevent transplant rejection because the resulting therapeutic tissues are created from a patient's own cells and are therefore genetically identical. Second, ACT's approach may provide an accessible source of cells to meet the demand for large quantities of transplantable tissues.

Advanced Viral Research
(ADVR.PK) 0.00

200 Corporate Blvd. South, Yonkers, NY 10701

Advanced Viral Research Corp is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases. Its flagship drug, Product R, is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS.

Advantagene, Inc.

440 Lexington Street, Auburndale, MA 02466

Advantagene is a privately held biotechnology company developing therapies to increase efficacy and reduce morbidity from the treatment of cancer. Advantagene’s drugs are designed to work with radiation, chemotherapy and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. The products are based on a technology called Gene Mediated Cytotoxic Immunotherapy (GMCI™), which is a unique and highly effective method of inducing a tumor-specific systemic immune response. Advantagene has two lead products in development. ProstAtak™, for prostate cancer and GliAtak™ for malignant glioma. In addition the company has a Phase I study open for its pancreatic cancer product, PancAtak™.

Albany Molecular Research, Inc
(AMRI) 6.36

21 Corporate Circle, PO Box 15098, Albany, NY 12212-5098 7001 Performance Drive, Syracuse, NY 13212 601 E. Kensington Road, Mount Prospect, IL 60056 18804 North Creek Parkway, Bothell, WA 98011

Albany Molecular Research, Inc. is a chemistry-based drug discovery and development company, focusing on applications for new small molecule prescription drugs. The company conducts R&D projects and collaborates with many leading pharmaceutical, biotechnology and genomics companies, and is developing new chemistry technology for potential prescription drug applications.

Aldor Corporation
(ADLR) 1.09

700 Pennsylvania Dr, Exton, PA 19341

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. Adolor was founded to capitalize on emerging proprietary development in cloned opioid receptors. The overall goal of the company's research effort is to develop products which maintain or improve opioid-like pain relief while reducing or eliminating opioid side effects. Entereg® (alvimopan), Adolor's lead product candidate, is an opioid receptor antagonist in late stage development to manage postoperative ileus, a negative gastrointestinal side effect following many types of surgery. Entereg is also being developed to manage the opioid-induced bowel dysfunction which can negatively impact quality of life for millions of patients using opioid analgesic products, such as morphine, for treating pain. Adolor is collaborating with GlaxoSmithKline for the development and commercialization of Entereg.

Alexion Pharmaceuticals Inc
(ALXN) 59.20

352 Knotter Dr SUITE 360, Cheshire, CT 06410

Alexion Pharmaceuticals, Inc. develops therapeutic products for the treatment of a wide array of severe diseases including cardiovascular and autoimmune disorders and cancer. The Company's two product candidates include Pexelizumab and 5G1.1. These products are antibodies that address specific diseases that arise when the human immune system attacks the human body itself and produces undesired inflammation. The Company is also developing Apogen immunotherapeutic products to target T-cell related disorders and is developing therapies employing the transplantation of cells from other species into humans, known as xenotransplantation. During the fiscal year 2001, the Company acquired Prolifaron, Inc.

Alfacell Corp.
(ACEL.PK) 0.26

300 Atrium Dr, Somerset, NJ 08873

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors.

Alkermes Inc
(ALKS) 13.87

64 Sidney St, Cambridge, MA 02139-4136

Alkermes Inc develops and commercializes therapeutic products based on drug delivery technologies. The Company has developed several drug delivery proprietary products that include ProLease (R), Medisorb (R), AIR (TM) and Cereport (R). ProLease (R) technology is used for the stabilization and encapsulation of fragile, protein and peptide based biopharmaceuticals in microspheres made of common medical polymers. Medisorb (R) is used for encapsulating traditional small molecule pharmaceuticals in microspheres made of common medical polymers. AIR (TM) technology system enables the delivery of both small molecules and macromolecules to the lungs. Cereport (R) drug delivery system increases transiently the permeability of the blood-brain barrier.

Alnylam Pharmaceuticals
(ALNY) 14.28

790 Memorial Drive, Suite 202, Cambridge, MA 02139

Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi. Using RNAi as a powerful product engine for creating a broad new class of therapeutics, Alnylam is building a deep pipeline of drug products that can treat a wide array of important diseases. Founded in 2002 by leading scientists who pioneered the discovery of RNAi, Alnylam is developing technology that can specifically and potently silence disease-causing genes. RNA interference is a natural cellular process for selectively turning off the activity of genes. By harnessing this natural process, Alnylam is developing novel therapeutics that use the natural RNAi mechanism to selectively turn off genes that produce proteins that play harmful roles in disease.

Alphagene

260 W. Cummings Park, Woburn, MA 01801

AlphaGene is functional genomics company offering products and services to biotech and pharmaceutical companies engaged in drug discovery and development. AlphaGene uses its large inventory of full-length, novel cDNAs and bioinformatics expertise to bridge the gap between genomics and functional proteomics. The company focuses on differential gene expression to identify potential drug targets, primarily for oncological and serious degenerative neurological diseases.

Alpharma, Inc.
(ALO) 10.00

One Executive Dr, Fort Lee, NJ 07024

Alpharma Inc. is a specialty pharmaceutical company with global leadership positions in products for humans and animals. Uniquely positioned to expand internationally, Alpharma is presently active in more than 60 countries. Alpharma is the largest manufacturer of generic liquid and topical pharmaceuticals in the U.S., and one of the largest suppliers of generic pharmaceuticals in selected European markets. Alpharma is among the world's largest producers of important specialty antibiotics, and is internationally recognized as a leading provider of animal health feed additives for poultry and livestock, and vaccines for farmed fish.

Alseres Pharmaceuticals
(ALSE.PK) 0.18

85 Main Street, Hopkinton, MA 01748

*Changed name from Boston Life Sciences in June 2007*
Alseres Pharmaceuticals is a biotechnology company engaged in the research and development of biopharmaceutical products for the diagnosis and treatment of Central Nervous System disorders. Our energy and focus in this area are reflected in several important initiatives. Our molecular imaging program has a product candidate, the ALTROPANE® molecular imaging agent, in phase 3 clinical development. ALTROPANE® is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or Essential Tremor. ALTROPANE is also being assessed in Phase II trials for diagnosing ADHD. Through our licensing and research collaboration with Children's Hospital Boston, Boston Life Sciences maintains a world-class position in the field of regenerating nerve axons. Our sponsored scientific research in this ground-breaking technology may someday make possible therapies leading to functional recovery following stroke, spinal cord and ocular injuries. Finally, our program in Parkinson’s Disease aims to provide a therapeutic solution to managing the symptoms as well as to slowing the progression of the disease.

Anika Therapeutics Inc
(ANIK) 5.20

160 New Boston St., Woburn, MA 01801

Anika Therapeutics develops, manufactures and commercializes therapeutic products intended to repair, protect and heal bone, cartilage and soft tissue. Our products are based on hyaluronic acid (HA), a biocompatible polymer found throughout the body that enhances joint function and coats, protects, cushions and lubricates soft tissues. Anika’s current commercial products focus on two areas: ophthalmic surgery and osteoarthritis conditions. Active new product development initiatives focus on novel HA formulations designed to prevent post-operative adhesions and a family of tissue augmentation therapies for cosmetic uses. Anika has considerable knowledge and expertise in the formulation and manufacturing of naturally derived HA. Our extraction and purification processes enable us to produce a premium-grade, ultra-pure, highly concentrated HA that has high molecular weight and viscocity, supporting both the efficacy and safety of our products.

Antigen Express, Inc.

100 Barber Avenue, Worcester, MA 01606

Antigen Express, Inc., a subsidiary of Generex, is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Their focus is on stimulating critical members of the immune response, known as T helper cells.

Antigenics Inc
(AGEN) 0.81

630 Fifth Avenue, Suite 2100, New York, NY 10111

The principal activities of the Group are developing treatments for cancers, serious infectious diseases, autoimmune disorders and degenerative disorders using our proprietary technologies to program the immune system and improve quality of life. These products include immunotherapeutics based on a specific class of proteins known as heat shock proteins, also referred to as HSPs, which activate powerful cellular immune responses, and Stimulon(R) based products, including QS-21. They base each product upon one of five technology platforms. The first two platforms, the heat shock proteins and QS-21 adjuvant, safely program cellular and antibody responses.The third platform is upon a receptor known as CD91 is at the heart of the pathway through which HSPs activate cellular immune response. The fourth platform represents a immunological pathway and the fifth platform, are a subset of T cells.

Applied Biosystems Group - Part of Applera Corp
*VENDOR/SERVICE*
(ABI) 12.10

301 Merritt 7, Norwalk, CT 06851-0001

Applied Biosystems Group, part of Applera, is principally involved in manufacturing and marketing instrument systems and associated consumable products for life science research and related applications.The products are used in biotechnology, environmental testing, food, human identification, agriculture and chemical manufacturing industries.The Company provides consulting, contract research and development services. The instruments are used by educational and research institutions, government agencies and other non-profit organizations. The Company has international operations in Europe, Japan, Latin America and other Far East countries.

Archemix

1 Hampshire Street, Cambridge, MA 02139

Archemix is developing pharmaceutical applications of aptamers (nucleic acid antibodies), and ribozymes (nucleic acid enzymes). Aptamers, the nucleic acid equivalent of antibodies, inhibit the biological activity of targets they bind. They thus directly compete with monoclonal antibodies (MAbs) as potential therapeutics in disease areas where target inactivation produces an appropriate patient response. The Archemix portfolio includes existing aptamers targeting a wide range of therapeutic targets including PDGF, TGF-b bFGF, hKGF, PSA, CD4, cytokines, complement system proteins, neutrofil elastase, thrombin, secretory PLA2, IgE, and selectins.

ARIAD Pharmaceuticals Inc
(ARIA) 3.57

26 Landsdowne St, Cambridge, MA 02139-4234

We are engaged in the discovery and development of breakthrough medicines to treat disease by regulating cell signaling with small molecules. Our initial disease focus is cancer, and we are developing a comprehensive approach that addresses the greatest medical need – novel therapies for aggressive and advanced-stage disease for which current treatments are inadequate. In oncology, our goal is to create a series of novel small-molecule product candidates that provide targeted and highly potent anti-cancer activity to treat both solid tumors and hematologic cancers, as well as the spread of primary tumors to distant sites. Our lead cancer product candidate, AP23573, is a potent mTOR inhibitor that starves cancer cells and shrinks tumors by regulating the response of tumor cells to nutrients and growth factors and by controlling tumor blood supply and angiogenesis through effects on vascular endothelial growth factor ("VEGF") in tumor and endothelial cells. Medinol Ltd. is also developing stents and other medical devices that deliver our lead product candidate to prevent reblockage at sites of vascular injury following stent-assisted angioplasty.

ArQule Inc
(ARQL) 5.53

19 Presidential Way, Woburn, MA 01801

ArQule designs optimal chemical entities (OCEs) using a multi-disciplinary approach that integrates intelligent molecule design and high-throughput, automated chemistry, in parallel, with predictive modeling of ADMET (absorption, distribution, metabolism, elimination, toxicity) parameters. These OCEs are target-relevant small molecules whose drug-like characteristics have been optimized prior to their entry into preclinical studies. ArQule believes that OCEs have greater likelihood of success through clinical trials.

Astralis Ltd
(ASTR.PK) 0.01

75 Passaic Avenue, Fairfield, NJ 07004

Astralis focuses on the research and development of novel treatments for immune system disorders and skin diseases. Astralis is currently working on the development of immunotherapeutics for the treatment of psoriasis, psoriatic arthritis, eczema, seborrheic dermatitis, and prostate enlargement.

AstraZeneca Int
(AZN) 51.41

P.O. Box 15437 Wilmington, DE 19850-5437

Large pharmaceutical.

Automated Cell

390 William Pitt Way, Pittsburgh, PA 15238

Automated Cell is a functional proteomics company focused in oncology and immune disease. Our Protein Function Factory is targeted at the determination, prioritization and validation of protein target, drug and antibody opportunities produced through genomics and proteomics discovery efforts.Ý Automated Cell collaborates with pharmaceutical and biotechnology partners to prioritize and validate their gene and protein libraries. Automated Cell also uses it proteomic platform of disease models, library creation, protein transduction, cellular phenotyping and bioinformatics for its own account to discover human proteins significant in disease. Automated Cell finds the proteins that cure diseases and dramatically focuses and shortens drug development efforts.

Avant Immunotherapeutics Inc
(CLDX) 3.45

119 Fourth Avenue, Needham, MA 02494-2725

AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines aimed a protecting travelers from cholera, typhoid fever and other illnesses. In addition, the company is conducting clinical studies of a proprietary vaccine candidate for cholesterol management. AVANT further leverages the value of its technology portfolio through corporate partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.

AVEO Pharmaceuticals

75 Sidney St, Cambridge, MA 02139

AVEO is a privately held, product-focused biopharmaceutical company in Cambridge, Massachusetts positioned to revolutionize cancer drug discovery and development. AVEO employs powerful, proprietary genetic model systems to discover and develop drugs against essential targets critical to the origin, maintenance and spread of malignant tumors. This novel high-throughput in vivo technology platform enables the rapid functional identification and prioritization of only the most relevant drug targets – dramatically improving the efficiency of drug discovery. Additionally, by identifying patient populations likely to be responsive to drug therapy, AVEO’s technology enables smarter drug development, decreased development costs and improved attrition.

Barrier Therapeutics
(BTRX) 0.00

600 College Road East, Suite 3200, Princeton, NJ 08540-6697

Barrier Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. Our goal is to develop a portfolio of innovative products that address major medical needs in the treatment of dermatological diseases and disorders. Our product pipeline includes eight product candidates in various stages of clinical development. These include treatements for dermatitis/eczema, fungal infections, yeast infections and congenital ichthyosis.

BG Medicine

40 Bear Hill Rd, Waltham, MA 02451

BG Medicine is a life sciences company focused on discovering novel biomarkers and commercializing innovative molecular diagnostic products that improve healthcare.

Bioarray Solutions

120 Centennial Ave, Piscataway, NJ 08854

BioArray Solutions has developed unique, proprietary technologies for the rapid and flexible analysis of DNA, proteins and cells on semiconductor chips. BioArray Solutions' optically programmable bead array technology enables a universal assay platform for next generation solutions in biomedical research, molecular diagnostics and drug development. The company offers complete assay solutions including on-demand, high volume production of custom chips along with proprietary assay designs and software analysis.

Biodel Inc.
(BIOD) 4.02

6 Christopher Columbus Avenue, Danbury, CT 06810-7352

Biodel's proprietary VIAdel™ technology allows for a more effective delivery of endocrine therapeutics as well as increased efficacy and safety. This patented technology is applicable to a wide range of peptides, proteins and other macromolecules. Biodel's lead drug candidates VIAject™, a very rapid-acting injectable insulin and VIAtab™, a very rapid acting oral sub-lingual insulin utilize VIAdel™ technology. Additionally, Biodel is developing other therapies, such as VIAmass™ and VIAcal™, to treat a variety of endocrine disorders based on the VIAdel™ technology.

Biogen IDEC
(BIIB) 57.17

14 Cambridge Center Cambridge, MA 02142 3030 Callan Rd, San Diego, CA 92121

In November 2003, Biogen Idec Inc. was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing expertise, global infrastructure, and financial position. Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing. Biogen Idec is dedicated to pursuing the creativity of science. The company’s products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and rheumatology.

Biopure Corp
(BPURQ.PK) 0.02

11 Hurley St, Cambridge, MA 02141

The mission of Biopure Corporation (Nasdaq: BPUR) is to introduce revolutionary new drugs that deliver lifesaving oxygen. Using it's patented and proprietary technology, Biopure has pioneered the development and manufacture of oxygen therapeutics, a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. The company's products represent a new Oxygen Bridge" treatment approach for managing patients' oxygen requirements in potential medical applications associated with ischemia or acute anemia.

BioSpecifics Technologies Corp.

35 Wilbur St., Lynbrook, NY 11563

ioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications. We have a development and licensing agreement with Auxilium Pharmaceuticals www.auxilium.com (Nasdaq GM: AUXL) for clinical indications in Dupuytren’s disease, Peyronie’s disease and frozen shoulder (adhesive capsulitis). Prior to March 2006, our primary focus was on the manufacture of the FDA licensed product collagenase ointment for use in debridement of dermal ulcers and severely burned areas. Following the sale of our collagenase topical business to DFB BioTech, we reorganized and concentrated all activities on the future development and commercialization of our injectable collagenase products.

Biovertis AG

Campus Vienna Biocenter 6, 1030 Vienna, Austria Gmunder Str. 37-37a, 81379 Munich, Germany

Biovertis is focusing on the development of novel classes of small molecule antibacterials.

Caliper Life Sciences
(CALP) 3.47

68 Elm St., Hoplinton, MA 01748 605 Fairchild Dr, Mountain View, CA 94043

Caliper Life Sciences provides leading microfluidic, liquid handling, and integrated laboratory automation solutions to the worldwide life science industry. Through its expertise in microfluidics, Caliper is uniquely positioned to lead the industry by evolving the company's liquid handling, detection, and integration platforms into technologically advanced LabChip systems that offer the efficiency, versatility, and exquisite data that key scientists in the pharmaceutical industry already rely on to drive their drug discovery programs.

Celgene Corporation
(CELG) 53.93

7 Powder Horn Drive, Warren, NJ 07059

Celgene is a pharmaceutical company with a major focus on the discovery, development and commercialization of small molecules for cancer and immunological diseases. Celgene's medical research and development team is working to extend the boundaries in the areas of small molecule immunotherapeutic and biocatalytic chiral chemistry by developing both new pharmaceuticals and chirally pure versions of existing drugs. Celgene's agrochemical unit, Celgro, is dedicated to the development of chirally pure crop protection agents. Our goal is to provide hope and ease suffering through the discovery and development of products for therapies for patients with severe and difficult to treat diseases.

Celldex Therapeutics, Inc.

222 Cameron Drive, Suite 400, Phillipsburg, NJ 08865 23 Cambridge Science Park, Cambridge CB4 0EY UK

Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious diseases and immune system disorders through our novel 'active immunization' approach. We have developed our Antigen Presenting Cell Targeting Technology (APC Targeting Technology™) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells, or APCs - particularly dendritic cells. We are using this technology approach to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many specific cancers, as well as within our growing activities in infectious disease and auto-immune disorders.

Cellomics
*VENDOR*

100 Technology Drive, Pittsburgh, PA 15219

Cellomics is automating drug discovery through a unique, cell-based product platform that combines ultra high throughput primary screening with complete systems for high content screening, including fluorescent reagents, kits, and cell lines, multiparametric assays, cell analysis instrumentation, informatics and cellular bioinformatics. Cellomics provides a complete platform for High Content Screening and automated cellular analysis.Our unique technology integrates fluorescence-based reagents, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetic systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences.

Cellular Genomics

36 East Industrial Rd, Branford, CT 06405

CGI has assembled a suite of powerful technologies designed to set new standards in genomic-based drug discovery. CGI's technologies couple unprecedented rigor in the identification and functional validation of drug targets with unique, proprietary model systems and tools designed to facilitate drug discovery itself. Further, CGI technologies have the capacity for implementation on a genome-wide basis, and are being adapted as high-throughput drug screens for rapid product identification and development.

Cephalon Inc
(CEPH) 60.70

41 Moores Road, Frazer, PA 19355 4745 Wiley Post Way, Salt Lake City, UT 84116 20 rue Charles Martigny 94701 Maisons-Alfort CEDEX FRANCE

Launched in 1987 by an enthusiastic young researcher, Dr. Frank Baldino, Jr., Cephalon’s growth has led to discoveries and new therapies for sleep disorders, neurological diseases, cancer, pain management and addiction. The company’s early focus on neurodegenerative disease led to breakthroughs in understanding the chemistry of what causes cells to die, insights that are now being applied to treating cancer as well as diseases of the central nervous system. At the same time, the company explored unmet patient needs in sleep medicine, becoming the market leader in treating wakefulness (www.provigil.com) and developing the only FDA approved treatment for shift-work sleep disorder. Our gains in these areas have allowed Cephalon to branch out into some promising new fields. The company is applying its knowledge about cell and molecular biology to some promising early-stage research in new cancer therapies.

Cetek Corp

260 Cedar Hill Street, Marlborough, MA 01752-3017

Cetek Corporation is a biopharmaceutical company engaged in the discovery and early development of novel cancer therapeutics based on the convergent application of its two core technologies: CE Assay™ and the Company's natural-product based drug sources. The broadly applicable CE Assay™ is Cetek's proprietary, high-throughout capillary electrophoresis technology that enables the rapid screening of difficult to assay drug targets as well as conventional targets. Interfacing with CE Assay™ is Cetek's proprietary natural product extract library and its emerging ChemSelect™ library of single-compounds and natural product-like synthetic derivatives.

Charles River Laboratories
(CRL) 29.72

251 Ballardvale Street, Wilmington, MA 01887-1000

Charles River Laboratories provides research models and laboratory animal support services, preclinical services, and clinical services to the biomedical market. We are focused on improving human and animal health by becoming the premier global company advancing the search for drugs from discovery through market approval.

Coley Pharmaceutical Group
(COLY) 0.00

93 Worcester Street, Suite 101, Wellesley, MA 02481 340 Terry Fox Drive, Suite 200 Ottawa, Ontario, K2K 3A2 CANADA Elisabeth-Selbert-Strasse 9 D40764 Langenfeld, GERMANY

Coley is focused on the discovery, development and commercialization of TLR Therapeutics that direct the immune system to fight disease. TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to fight disease. TLRs detect molecules that are unique to foreign invaders, or pathogens, and which distinguish intracellular pathogens, such as viruses and retroviruses, from extracellular pathogens, such as most bacteria and fungi. Our TLR Therapeutics are synthetic nucleic acids that function as stimulators, or as blockers, of one or more TLRs that are found in immune cells. Each of our product candidates are all short DNA-like molecules, with distinct motifs, or nucleotide sequences, that possess potent immunomodulatory properties which direct different immune system functions.

CollaGenex Pharmaceuticals Inc
(CGPI) 0.00

41 University Dr, Newtown, PA 18940

CollaGenex is developing dermatological applications of its proprietary IMPACS™ technology. Oracea® (doxyxcycline, USP) 40 mg* was approved by the FDA on May 26, 2006. Oracea is now commercially available. Oracea is anti-inflammatory dose doxycycline. Incyclinide formerly known as Col-3 is in Phase II clinical trials for the treatment of acne. CollaGenex is developing additional products for dermatology based on Restoraderm®, a novel drug delivery technology.

Covance, Inc.
*VENDOR/SERVICE*
(CVD) 38.87

210 Carnegie Ctr, Princeton, NJ 08540-6233

Covance — one of the world's largest and most comprehensive drug development services companies — has the people, global resources and problem-solving culture to respond to pharmaceutical and biotechnology clients' toughest drug development challenges. We provide a portfolio of preclinical and clinical development and commercial service offerings — delivered through industry-leading nonclinical testing services, the world's largest central laboratory network, and a global team of clinical trial professionals and cardiac safety experts.

Cubist Pharmaceuticals Inc
(CBST) 23.20

65 Hayden Avenue, Lexington, MA 02421

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that address unmet medical needs in the acute care environment. The company is headquartered in Lexington, Massachusetts. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first IV antibiotic from a class of antiinfectives called lipopeptides.

CuraGen Corp
(CRGN) 1.37

322 East Main Street, Branford, CT 06405

CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen’s deep understanding of the human genome has enabled us to gain greater insight into the molecular basis of disease. The Company's therapeutics are based on novel drug targets that are believed to play a role in proven mechanisms underlying disease. CuraGen has translated this understanding into a pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes. The Company’s strategy remains focused on advancing its pipeline of promising therapeutics through clinical and preclinical development.

Curis Inc
(CRIS) 1.33

45 Moulton Street, Cambridge, MA 02138

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease.

Cyclacel Ltd
(CYCC) 1.54

James Lindsay Place, Dundee Technopole, Dundee DD1 5JJ UK 200 Connell Drive #1500 Berkeley Heights, NJ 07922

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our science, management and expertise in cell cycle biology are the core of our business strategy. We have a deep pipeline that includes: seliciclib (CYC202) and sapacitabine (CYC682), in clinical trials for the treatment of cancer; an Aurora kinase and VEGFR2 inhibitor (CYC116) at the IND submission stage; a large portfolio of development candidates; and a productive drug discovery engine.

Cytogen Corporation
(CYTO) 0.00

650 College Road East, Suite 3100, Princeton, NJ 08540

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen introduced its fourth approved oncology product to the U.S. market, CAPHOSOL®, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer.

Cytyc Corporation
(CYTC) 0.00

250 Campus Drive, Marlborough, MA 01752

Cytyc Corporation is a diversified diagnostic and medical device company that designs, develops, manufactures, and markets innovative and clinically effective diagnostic and surgical products. Cytyc's products cover a range of cancer and women's health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of early-stage breast cancer, and radiation treatment of patients with malignant brain tumors.

D-Pharm

Kiryat Weizmann Science Park, Bldg. 7, P.O. Box 2313, Rehovot 76123, Israel 47 Hulfish Street, Suite 310 Princeton, NJ 08642

D-Pharm is a specialty pharmaceutical company that designs and develops innovative drugs for the treatment of the most devastating brain disorders. The Company has developed two unique platform technologies that generate lipid–like medicines which utilise lipid specific mechanisms and lipid-related pathways in living cells. Additional therapeutic applications for DP-b99 include: Traumatic Brain Injury (TBI) and diminishing the risk of brain damage associated with Coronary Artery Bypass Graft surgery (CABG); and for DP-VPA include Bipolar disorder and prophylaxis of Migraine. In addition, the Company possesses a pipeline of pre-clinical candidates for treatment of neuro-degenerative diseases, other CNS disorders and cancer. The most advanced of these candidates is DP-460 for the treatment of Alzheimer’s disease.

Discovery Labs
(DSCO) 0.23

2600 Kelly Road, Suite 100, Warrington, PA 18976

Discovery Labs is developing its SRT™ platform with the intent to create a completely new therapeutic approach in the treatment of respiratory disease. Product introduction begins with anticipated U.S. FDA approval of SURFAXIN®, followed by the potential launch of multiple line extensions involving a variety of dosage forms and novel indications of usage. AEROSURF™, Discovery Labs' aerosolized surfactant candidate, represents a potential transformation in respiratory critical care by reducing or eliminating complications associated with mechanical ventilation.

DOV Pharmaceuticals

150 Pierce St., Somerset, NJ 08873

DOV Pharmaceutical is a biopharmaceutical company focused on the discovery, acquisition and development of novel drug candidates for CNS disorders. We have active drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (entering Phase II for depression), DOV 102,677 (Phase I for alcohol abuse) and an active preclinical discovery program in reuptake inhibitors and GABA modulators.

DUSA Pharmaceuticals Inc
(DUSA) 2.21

25 Upton Drive, Wilmington, MA 01887

DUSA Pharmaceuticals, Inc.® is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. DUSA's other dermatology products include ClindaReachTM, Nicomide® and the AVAR® line. DUSA is also researching additional indications for internal uses of Levulan PDT.

Dyax Corp
(DYAX) 2.54

300 Technology Square, Cambridge, MA 02139 Building 22, Boulevard du Rectorat 27B,Sart Tilman B-4000 Liege 1 Belgium

Our therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation. Our powerful discovery technology provides us the uncommon advantage of being able to both identify and then develop our own clinical leads. Our integrated approach also allows us to leverage this technology into revenue generating collaborations with other companies and researchers to further their own product pipelines.

Eisai Inc.

100 Tice Blvd.,Woodcliff Lake, NJ 07677 900 Davis Drive, P.O. Box 14505, Research Triangle Park, NC 27709

Eisai's research and development emphasis is on four therapeutic areas - neurology, gastrointestinal disorders, cancer and acute care. The company has three products on the U.S. market. These include treatments for: Alzheimer's disease, gastrointestinal disorder, and status epilepticus -- a condition in which one major convulsive attack follows another with little or no intermission. Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd.

EluSys Therapeutics Inc.

P.O. Box 102, 25 Riverside Drive, Pine Brook, NJ 07058

Elusys Therapeutics, Inc. develops novel antibody-based therapies using its proprietary technology and expertise in Heteropolymer (HP) antibody chemisty and complement biology. The Company is developing a pipeline of products for the treatment of infectious diseases, autoimmune diseases, biowarfare agents and cancer. Elusys? antibody products work in concert with the body?s own defense system to more effectively remove pathogens and disease-specific antigens from the circulation. Elusys currently has several products in various stages of preclinical and clinical development.

EMD Serono, Inc.

One Technology Place, Rockland, MA 02370

As the US affiliate of Merck Serono S.A., a global biotechnology leader headquartered in Geneva, Switzerland, EMD Serono, Inc. is an integral part of driving the growth and success of the company's global business.EMD Serono, Inc. is committed to discovering and developing medicines that address significant unmet medical needs. Serono has built its reputation as a leader in the industry by integrating cutting-edge science with comprehensive patient support systems to improve people's lives. With a focus on specialized therapeutic areas, including reproductive health, neurology and metabolic endocrinology, we are committed to growing our current therapeutic areas and entering into new ones by developing both biotherapeutic proteins and small molecules.

Emisphere Technologies Inc
(EMIS.OB) 1.05

765 Old Saw Mill River Road, Tarrytown, NY 10591

Emisphere Technologies, Inc. is a biopharmaceutical company charting new frontiers in drug delivery. Our core business strategy is to develop oral forms of injectable drugs, either alone or with corporate partners, by applying our proprietary eligen® technology to these drugs. Emisphere has strategic alliances with world-leading pharmaceutical companies.

Enanta Pharmaceuticals, Inc.

500 Arsenal Street, Watertown, MA 02472

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. Enanta is commited to the application of innovative chemistry that surpasses traditional medicinal chemistry approaches. The Company’s successful integration of chemistry with biology has created a new class of macrolide antibiotics, called Bicyclolides, which overcome bacterial resistance.

Enzo Biochem, Inc.
(ENZ) 3.74

527 Madison Avenue, New York, NY 10022

Developing technology platforms for detecting and identifying genes and for modifying gene expression and regulating immune function, with application to the therapeutic, diagnostic and research markets.

Enzon Inc
(ENZN) 10.88

685 Route 202/206, Bridgewater, NJ 08807 20 Kingsbridge Road Piscataway, NJ 08854

We are a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. Our specialized sales force markets ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT® in North America. In addition, we also receive royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals and Pfizer Inc. Our product-driven strategy includes an extensive drug development program that leverages our proprietary technologies, including a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate.

EpiCept Corp
(EPCT) 0.61

777 Old Saw Mill River Road Tarrytown, NY 10591 6650 Nancy Ridge Drive San Diego, CA 92121 Goethestraße 4 D-80336 Munich, Germany

EpiCept is focused on developing novel, effective, safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes.

EPIX Pharmaceuticals

4 Maguire Rd, Lexington, MA 02421 S.A.P. Building, 3 Hayetzira St, Ramat-Gan 52521 Israel

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity.

Exact Sciences Corp
(EXAS) 5.38

100 Campus Drive, Marlborough, MA 01752

EXACT Sciences is an applied genomics company founded in 1995. The Company’s mission is to develop technologies that help to eradicate mortality from common cancers — starting with colorectal cancer — by applying advances in the field of genomics to facilitate the early detection of disease. EXACT Sciences’ first target is colorectal cancer, the second leading cause of cancer deaths and the most deadly cancer among non-smoking men and women in the United States.

FoldRx Pharmaceuticals

100 Acorn Park Drive, 5th Floor, Cambridge, MA 02140

FoldRx is a leader in the discovery and development of first in class disease modifying drug therapies for diseases of protein misfolding and amyloidosis. Misfolded protein is an emerging concept that has recently begun to gain momentum in the scientific community as the underlying cause of many chronic and late onset diseases such as Parkinson's, Alzheimer's, Huntington's disease, Cardiomyopathy, and Polyneuropathy.

Forest Laboratories Inc.
(FRX) 29.61

909 Third Avenue, New York, NY 10022

Forest Laboratories develops, manufactures and sells both branded and generic forms of ethical products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses. Lexapro is one of the fastest-growing SSRI antidepressant in the United States. Benicar has become an important treatment option for hypertension. Namenda is the first approved therapy in the United States for those with moderate or severe Alzheimer's disease.

Gemin X Pharmaceuticals, Inc.

3576 Avenue du Parc, Suite 4310 Montreal, QC, H2X 2H7 Canada 400 Chesterfield Parkway, Suite 100, Malvern, PA 19355

Gemin X Pharmaceuticals, Inc., specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in Phase 1 clinical trials in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montréal, Québec.

Genaera
(GENR.PK) 0.00

5110 Campus Drive, Plymouth Meeting, PA 19462

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes. In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

GeneData AG
*SERVICE*

Maulbeerstrasse 46 CH-4016 Basel SWITZERLAND Lena-Christ-Str. 50 D-82152 Martinsried GERMANY Suite 194 1601 Trapelo Road, Waltham, MA 02451 601 Gateway Blvd, Suite 610, South San Francisco, CA 94080-7001

Genedata provides sophisticated computational solutions for life science research using a combination of software systems and professional services developed in close collaboration with its customers and partners.

Genencor Intl Inc

200 Meridian Centre Blvd., Rochester, NY 14618-3916 925 Page Mill Road, Palo Alto, CA 94304

The company produces protein (enzyme) products used for industrial applications in diverse consumer and industrial markets, ranging from grain processing to cleaning and textiles to biofuels and biosafety.

Genmab A/S

Toldbodgade 33, 1253 Copenhagen K Denmark Yalelaan 60, 3584 CM Utrecht, The Netherlands 457 North Harrison Street, Princeton, NJ 08540 USA 17b Hermitage Road, Hitchin, Hertfordshire SG5 1BT, UK

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products.

Genta Inc
(GETA.OB) 0.97

200 Connell Drive, Berkeley Heights, New Jersey 07922

Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of patients with cancer. Genta’s pipeline is anchored by two key programs: RNA/DNA Medicines (which include products that employ Antisense, RNA interference and Decoys ); and Small Molecules . The products from each of these platforms address significant unmet medical needs. The Company’s lead drug from its RNA/DNA Medicines program is Genasense® (oblimersen sodium). Genasense is currently in late-stage clinical trials for the treatment of melanoma, multiple myeloma, chronic lymphocytic leukemia, non-small cell lung cancer, small cell lung cancer and prostate cancer. In December 2003, Genta submitted a New Drug Application (NDA) for Genasense plus chemotherapy for the treatment of patients with advanced malignant melanoma to the U.S. Food and Drug Administration. The Company’s leading drug from its Small Molecules program is Ganite® (gallium nitrate injection). The Company launched Ganite in September 2003 for the treatment of cancer related hypercalcemia that is resistant to hydration.

Genzyme Corporation
(GENZ) 70.43

500 Kendall Street, Cambridge, MA 02142

One of the world’s foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in Boston in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $3 billion and more than 9,000 employees in locations spanning the globe. With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial research and development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

GTC Biotherapeutics
(GTCB.OB) 0.32

175 Crossing Blvd., Framingham, MA 01702

*Previously Genzyme Transgenics Corp*
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn® is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.

Hemispherx BioPharma Inc
(HEB) 0.52

One Penn Center, 1617 JFK Blvd., 6th Floor, Philadelphia, PA 19103

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®.

Hepalife Technologies
(HPLF.OB) 0.09

60 State St., Suite 700 Boston, MA 02109

Working with our unique and patented cell-based technologies, our scientists hope to improve the quality of life for those with liver disease. To make all drugs safer by developing better toxicity testing. And to ward off pandemic flu with a vaccine that is faster to produce.

Hypnion

500 Patriot Way, Lexington, MA 02421

Hypnion Inc. is a wholly owned subsidiary of Eli Lilly and Company (www.lilly.com). We are focused on the development of novel therapeutics for the treatment of central nervous system (CNS) disorders to serve the vastly underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. Utilizing our proprietary drug discovery technology, SCORE-2004™, the world’s only predictive sleep-wake bioassay system, we are able to rapidly and accurately measure a drug’s impact on a wide spectrum of sleep and wake parameters, in a manner that is highly predictive of the human condition.

Hypromatrix
*VENDOR/SERVICE*

100 Barber Avenue, Worcester, MA 01606

Hypromatrix is a proteomics-based biotechnology company dedicated to provide high quality and high throughput protein assay systems to the biomedical research community and the biopharmaceutical industry. Hypromatrix AntibodyArray(TM) is designed to detect protein-protein interactions based on our patented technology.

Idenix Pharmaceuticals
(IDIX) 3.13

60 Hampshire Street, Cambridge, MA 02139 1682 Rue De Le Valsiere 34189 Montpellier, Cedex 4 France

denix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV).

Idera Pharmaceuticals, Inc.
(IDRA) 3.36

167 Sidney Street, Cambridge, MA 02139

Idera Pharmaceuticals is a biotechnology company engaged in the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases, including: cancer, infectious diseases, asthma/allergy, autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines.

Illumina Inc
(ILMN) 45.00

9885 Towne Centre Drive, San Diego, CA 92121-1975 50 Barnes Park North Wallingford, CT 06492

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

ImClone Systems, Inc.
(IMCL) 69.67

180 Varick Street, New York, New York 10014

mClone Systems is dedicated to developing and commercializing novel therapeutic products in the field of oncology. Our efforts have resulted in a broad spectrum of innovative product candidates with potential application in multiple tumor types.

Immtech Intl Inc
(IMM) 0.00

One North End Avenue, New York, NY 10282 150 Fairway Drive, Suite 150, Vernon Hills, IL 60061

Immtech is discovering, developing and commercializing drugs for the treatment of: (i) fungal and other infectious diseases such as tuberculosis, hepatitis, pneumonia, diarrhea and AIDS and (ii) cancer, through both the Company's pharmaceutical program, operated by a joint venture company, NextEra Therapeutics, Inc., its biological program. The Company has two disciplines for developing new drugs, a pharmaceutical program and a biological program. The pharmaceutical program focuses on the discovery, development and commercialization of drugs to treat fungal, parasitic, bacterial and viral diseases. The biological program is operated through a joint venture with the Franklin Research Group in a Company called NextEra.

ImmuCell Corporation
(ICCC) 3.00

56 Evergreen Drive, Portland, ME 04103

ImmuCell is a public biotechnology company dedicated to marketing products that improve animal health and productivity in the dairy and beef industries. Our product focus encompasses prevention, diagnosis and treatment of bovine diseases. ImmuCell continues to be on the forefront of calf scours (diarrhea) prevention technology, manufacturing and marketing First Defense®, the most popular and convenient scours prevention administered to calves. It’s the only USDA approved scours preventative administered to calves with indications for E. coli and coronavirus.

ImmunoGen
(IMGN) 5.50

128 Sidney Street Cambridge, MA 02139

Our mission is to be the leader in the application of monoclonal antibodies for the treatment of cancer. We aim to achieve this by exploiting our expertise and experience in the identification of potential biological targets for cancer treatments, the development and humanization of monoclonal antibodies, and the creation of potent cell-killing agents designed for delivery by antibodies. Our Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a highly potent cell-killing agent specifically to cancer cells to kill these cells with minimal damage to healthy tissue.

Immunomedics, Inc.
(IMMU) 3.05

300 American Road, Morris Plains, NJ 07950

Immunomedics’ mission is to improve patients’ health and extend life by focusing on the development, manufacture and commercialization of humanized monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

IMPAX Laboratories

30831 Huntwood Avenue, Hayward CA 94544 3735 Castor Avenue, Philadelphia, PA 19124

The mission for IMPAX Laboratories is to become a leader in the development, manufacturing and marketing of specialty prescription pharmaceutical products utilizing our formulation expertise and unique drug delivery technologies.

Incyte
(INCY) 13.65

Experimental Station, Route 141 & Henry Clay Road, Building E336, Wilmington, DE 19880

Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have active internal drug discovery programs focused on the identification of novel small molecule drugs for inflammation, cancer and diabetes and we recently entered into a collaborative license agreement for Reverset™, a novel nucleoside analog reverse transcriptase inhibitor, which is in Phase II development to treat human immunodeficiency virus (HIV) infections. Data from preclinical and clinical studies of Reverset though Phase IIa suggest the drug may be a useful and convenient HIV treatment, particularly among the many patients who have become resistant to standard HIV therapies.

Indevus Pharmaceuticals
(IDEV) 0.00

33 Hayden Avenue, Lexington, MA 024211 7 Clarke Drive Cranbury, New Jersey 08512

We identify and acquire products and product candidates that have differentiating features for multiple therapeutic areas. The Company has a primary commitment to urology and endocrinology. We are focused on individual compounds, rather than on earlier stage, relatively unproven drug discovery technologies.

Infinity Pharmaceuticals
(INFI) 4.82

780 Memorial Drive, Cambridge, MA 02139

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. IPI-504, our lead product candidate, is currently being studied in two disease-focused Phase I clinical trials. IPI-504 is a proprietary, targeted cancer therapy that inhibits heat shock protein 90, or Hsp90. Our next most advanced program is directed against the Hedgehog cell signaling pathway. The Hedgehog pathway is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and is implicated in many of the most deadly cancers. The goal of our third program is to identify small molecule compounds that inhibit the Bcl-2 family of proteins. Using our proprietary small molecule drug discovery technologies, we have identified selective inhibitors of Bcl-2 and its related protein family member, Bcl-xL.

Integra Lifesciences
(IART) 37.21

311 Enterprise Drive Plainsboro, NJ 08536

Integra is a market-leading, innovative medical device company focused on helping the medical professional enhance the standard of care for patients. Integra provides customers with clinically relevant, innovative and cost-effective products that improve the quality of life for patients. We focus on cranial and spinal procedures, peripheral nerve repair, small bone and joint injuries, and the repair and reconstruction of soft tissue. Our product lines include Neurosurgical / Orthopedic Implants and Medical / Surgical Equipment. Our Neuro/Ortho Implants product group includes dural grafts that are indicated for the repair of the dura mater, dermal regeneration and engineered wound dressings, implants used in small bone and joint fixation, repair of peripheral nerves, and hydrocephalus management, and implants used in bone regeneration and in guided tissue regeneration in periodontal surgery. Our MedSurg Equipment product group includes ultrasonic surgery systems for tissue ablation, cranial stabilization and brain retraction systems, instrumentation used in general, neurosurgical, spinal and plastic and reconstructive surgery and dental procedures, systems for the measurement of various brain parameters, and devices used to gain access to the cranial cavity and to drain excess cerebrospinal fluid from the ventricles of the brain.

Interleukin Genetics Inc
(ILIU.PK) 0.25

135 Beaver Street, Waltham, MA 02452

Interleukin Genetics is the only company that has developed a DNA based risk assessment test that can tell people whether or not they have a genetic risk factor that affects their own inflammatory response. Chronic inflammation is now thought to be an important risk factor for heart disease, and interleukin-1 (IL-1) genetic variations have been shown to be an indicator of early cardiac events. Interleukin Genetics is also the only biotechnology company that has a strategic alliance with a large consumer products company that markets a nutritional product designed for people who test positive for specific IL-1 genetic variations.

Lexicon Pharmaceuticals, Inc.
(LXRX) 1.49

8800 Technology Forest Place The Woodlands, TX 77381-1160 350 Carter Road Princeton, NJ 08540

Lexicon is focused on the discovery and development of breakthrough treatments for human disease. We have used our proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease.

LifeCell Corp
(LIFC) 0.00

One Millennium Way, Branchburg, NJ 08876-3876

LifeCell Corporation was formed in 1986 to market a unique tissue preservation technology developed by Dr. Stephen Livesey, M.D., Ph.D. and his colleagues at the University of Texas. The cryopreservation technique that they perfected allowed them to freeze-dry biological tissues and cells without damaging their structural or biochemical integrity. Over the next several years, LifeCell’s team of scientists worked to broaden the applications of this technology to a variety of tissues, including dermis, blood vessels and nerves. The ultimate result was an acellular tissue matrix that resists infection and rejection, can be stored for long periods, and is as strong as synthetics while being far more pliable - enabling the human body to regenerate lost tissue in the same way that it naturally replaces damaged or inadequate tissue throughout life. LifeCell’s first clinical product, AlloDerm®, was brought to market in 1994. Used for a variety of applications, AlloDerm has improved the lives of tens of thousands of patients across the country by restoring the precious gift of natural healing.

Locus Pharmaceuticals, Inc.

4 Valley Square, 512 E. Township Line Road, Blue Bell, PA 19422

Locus Pharmaceuticals is focused on developing novel, small molecule therapeutic drugs to address major unmet medical needs. Our proprietary computational technology rapidly and accurately identifies the biologically relevant active binding site(s) of a protein and simultaneously designs de novo novel, small molecule antagonist or agonists of the protein’s activity utilizing our proprietary fragment data set. Unlike traditional high throughput screening technologies, the Locus process is a de novo fragment-based approach that enables the identification of novel small molecule drug candidates faster and on a larger scale than has previously been possible.

Lundbeck Research USA, Inc.

215 College Road Paramus, NJ 07652-1431

Lundbeck Research USA is engaged in drug discovery aimed at treating CNS diseases by designing small molecule therapeutics. Lundbeck Research USA is a world-leader in G Protein-Coupled Receptor discovery research.

Matritech Inc
(MZTH.PK) 0.03

330 Nevada Street, Newton, MA 02460

Matritech is a leading developer of proteomics-based diagnostic products for the early detection of cancer. Using its patented proteomics technology, Matritech has identified proteins correlated with bladder, cervical, breast, prostate and colon cancers. Matritech is one of the first companies to successfully employ proteomics to create diagnostic products

Medarex Inc
(MEDX) 0.00

707 State Road, Princeton, NJ 08540-1437

Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners.

Memory Pharmaceuticals
(MEMY) 0.14

100 Philips Parkway Montvale, NJ 07645

Memory Pharmaceuticals is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders, many of which exhibit significant impairment of memory and other cognitive function. These conditions include neurological diseases associated with aging, such as Alzheimer’s disease, and also include certain psychiatric disorders such as schizophrenia, bipolar disorder and depression.

Merck & Company, Inc.
(MRK) 35.84

One Merck Dr, Whitehouse Station, NJ 08889-0100

Merck is a research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products and provides pharmaceutical benefit services.

Millennium Pharmaceuticals Inc
(MLNM) 0.00

40 Landsdowne Street, Cambridge, MA 02139 Building 3, Chiswick Park, 566 Chiswick High Road, Chiswick, London W4 5YA UK

Millennium Pharmaceuticals currently markets INTEGRILIN® (eptifibatide) Injection for certain cardiovascular indications, and played a leading role in bringing the oncology drug Campath® (alemtuzmab) Injection to market.

Momenta Pharmaceuticals

675 West Kendall Street, Cambridge, MA 02142

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Through its discovery program, the Company is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars' functions in biological processes, with an initial focus in oncology.

Mylan Laboratories Inc.
(MYL) 17.73

1500 Corporate Drive, Suite 400, Canonsburg, PA 15317

Mylan is a global pharmaceutical company with market leading positions in generic pharmaceuticals, transdermal technology and unit dose packaged products. We focus on providing an extensive line of affordable, high quality prescription drugs in traditional and innovative dosage forms, and we enjoy a well-deserved reputation for scientific expertise in creating difficult-to-formulate and high-barrier-to-entry generic products.

Neurogen Corp
(NRGN) 0.00

35 NE Industrial Rd., Branford, CT 06405

Neurogen is a small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from pain, insomnia, inflammation, depression, and obesity.

Neuronyx Inc.

1 Great Valley Parkway, Suite 20, Malvern, PA 19355

Neuronyx has taken a deliberate commercial approach to the use of cellular therapies initially focused on ischemic diseases. The company's scientists have identified and isolated a novel population of human adult bone marrow-derived somatic cells (hABM-SC) with the potential to treat a number of diseases because of their demonstrated ability to repair, regenerate and remodel damaged tissues in preclinical studies. Our proprietary technology allows us to produce these cells efficiently and in large quantities for evaluation as medical therapies in numerous clinical applications. We believe Neuronyx is the first company to test hABM-SC directly in cardiac tissue of patients who have suffered a heart attack. Our lead product candidate, NX-CP105, is currently being tested for safety in a Phase 1 open-label single-escalating-dose study in patients who have suffered a heart attack.

Neurotech

6 Blackstone Valley Place, Suite 500, Lincoln, RI 02865

Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Retinal diseases represent significant unmet medical needs for which new medical therapies are the largest market opportunity in ophthalmology. Neurotech’s lead product (NT-501) is in clinical development for the treatment of retinal degeneration, including retinitis pigmentosa (RP), an inherited disease leading to blindness, and geographic atrophy, a serious condition associated with atrophic (dry) macular degeneration.

NexMed
(NEXM) 2.02

89 Twin Rivers Drive, East Windsor, NJ 08520

exMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, arthritis, sexual disorders and more.

Nitromed
(NTMD) 0.00

45 Hayden Road, Suite 3000, Lexington, MA 02421

NitroMed® is focused on the research, development and commercialization of proprietary pharmaceuticals based on the therapeutic benefits of the naturally occurring molecule nitric oxide. The goal is to become a leading, multi-product pharmaceutical company by developing innovative nitric oxide products. The Company's lead drug, BiDil®, was approved by the U.S. Food and Drug Administration (FDA) June 23, 2005. BiDil is indicated for the treatment of heart failure as an adjunct to current standard therapy in self-identified black patients, to improve survival, prolong time to hospitalization for heart failure and improve patient-reported functional status. NitroMed is directly marketing BiDil to physicians who treat black patients with heart failure.

Nucleonics

702 Electronic Drive, Horsham, PA 19044

Nucleonics is focused on developing therapeutic products based upon proprietary RNAi technologies, and proprietary manufacturing methods, formulations and delivery techniques. Also works with expressed inhibitory ds RNA (eiRNA).

Nymox Pharmaceutical Corp
(NYMX) 3.74

Heights Plaza, 777 Terrace Avenue 3rd Floor, Hasbrouck Heights, NJ 07604 9900 Cavendish Boulevard, Suite 306, St.-Laurent, Quebec, Canada H4M 2V2

Nymox Pharmaceutical is specializing in the research and development of therapeutics and diagnostics for the aging population. Nymox has an extensive pipeline of products under development, including therapeutics for enlarged prostate (BPH), a common affliction of males over the age of 50, and for Alzheimer's disease, the most common cause of dementia in the elderly. The company has global patent rights for the use of statins to treat or prevent Alzheimer’s disease. Nymox also has therapeutics in development for other indications, including deadly E. coli O157 food contamination, a major public health concern.

OMRIX Biopharmaceuticals, Inc.
(OMRI) 18.13

630 5th Avenue, 22nd Floor, New York, NY 10111 Ch de Waterloo 200, 1640 Rhode St Genèse, Brussels, Belgium MDA Blood Center, Tel Hashomer Hospital, 52621 Tel Aviv, Israel

Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market, which we believe is the fastest growing segment of the surgical sealant market. We are currently partnered with Ethicon Inc., a Johnson & Johnson Company, in the development of unique biosurgical devices which will meet critical unmet medical needs. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia immunoglobulin, or VIG, to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack . We currently market in Israel intravenous immunoglobulin, or IVIG, an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B immune globulin (HBIG), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.

Orapharma, Inc.

732 Louis Drive, Warminster, PA 18974

*Subsidiary of J&J*
OraPharma develops and commercializes therapeutics for oral health. OraPharma's initial product, ARESTIN®, represents a promising therapeutic advance for the adjunct treatment of periodontal disease. ARESTIN® is the first locally administered time-released antibiotic encapsulated in microspheres that effectively kills the germs that cause periodontal disease or periodontitis, a disease that affects more than 50 million people in the U.S.

OraSure Technologies, Inc

220 East First Street, Bethlehem, PA 18015

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices.

Orchid Celmark
(ORCH) 1.43

4390 US Route One, Princeton, NJ 08540

Orchid Cellmark is a leading provider of identity DNA testing services for the human identity and agriculture markets. In the human identity area, the company provides DNA testing services for forensic, family relationship and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for food safety and selective trait breeding.

Oscient Pharmaceuticals
(OSCIQ.PK) 0.01

1000 Winter Street, Suite 2200, Waltham, MA 02451

Oscient Pharmaceuticals Corporation is a commercial-stage biopharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).

OSI Pharmaceuticals, Inc
(OSIP) 0.00

41 Pinelawn Road, Melville, NY 11747 2860 Wilderness Place, Boulder, CO 80301 Watlington Road Oxford, OX4 6LT, UK

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms. Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity.

OXiGENE Inc
(OXGN) 0.28

230 Third Avenue, Waltham, MA 02451 Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA

OXiGENE’s business strategy is to identify and in-license compounds complimentary to the Company’s existing pipeline from academic institutions, lead them through clinical trials, and establish partnerships with pharmaceutical and biotechnology companies to further develop, manufacture, and commercialize the compounds. OXiGENE is currently focusing on two market areas, oncology and ophthalmology.

Palatin Technologies, Inc.
(PTN) 0.18

4-C Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512

Palatin Technologies is focused on discovering and developing melanocortin (MC)-based therapeutics. The Company is currently conducting clinical trials with its lead drug Bremelanotide (formerly PT-141), a MC receptor agonist, for the treatment of male and female sexual dysfunction. Palatin’s patented drug discovery platform, MIDAS™, streamlines the drug discovery process with an efficient approach to creating lead compounds based on protein conformation.

Panacos
(PANC.PK) 0.01

134 Coolidge Avenue, Watertown, MA 02472 209 Perry Parkway, Suite 7 Gaithersburg, MD 20877

Panacos' scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Panacos merged with V.I. Technologies, Inc. (Vitex), a biotechnology company developing products designed to improve the safety of the world's blood supply. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development.

PAR Pharmaceuticals
*SPECIALTY/GENERIC*
(PRX) 27.39

300 Tice Boulevard, Woodcliff Lake, NJ 07677 One Ram Ridge Road, Spring Valley, NY 10977

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. In July 2005, Par received approval for and introduced Megace® ES, the company's first branded pharmaceutical product.

Pfizer
(PFE) 16.70

235 East 42nd Street, New York, NY 10017

Large pharmaceutical.

Pharmacopeia, Inc.
(PCOP) 0.81

3000 Eastpark Blvd., Cranbury, NJ 08512

Pharmacopeia is a biopharmaceutical company developing small molecule therapeutics. Pharmacopeia's programs leverage the company's immunobiology expertise and are focused on diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis.

Phytomedics

1085 Cranbury South River Road, Suite #8, Jamesburg, NJ 08831-3410

Phytomedics possesses a broad and innovative proprietary technology platform that enables it to discover, develop and manufacture novel botanical therapeutics, including botanical drugs (as recently defined by the U.S. FDA), nutraceuticals/dietary supplements, cosmeceuticals, functional/medicinal foods, and plant-produced biologics. Through state-of-the-art, proprietary approaches, Phytomedics' botanical therapeutics program reconnects plants and healthcare at a new level of technological sophistication.

Point Therapeutics
(POTP) 0.00

155 Federal Street, Fourth Floor, Boston, MA 02110

Point Therapeutics, Inc is a Boston-based biopharmaceutical company developing a family of dipeptidyl peptidase (DPP) inhibitors for oncology and type 2 diabetes.

Predictive Biosciences

128 Spring Street, 400 Level, B Annex, Lexington, MA 02421

Leveraging its portfolio of patented biomarkers and proteomics technologies, Predictive Biosciences is pioneering novel diagnostic assays for informed cancer management™ – to significantly improve care and reduce healthcare costs for cancer patients. The company's products will enable real-time cancer diagnostics™ and cancer monitoring by detecting the physiological changes resulting from cancer development and progression. These assays will provide physicians with the information to treat patients in a timelier and personalized manner, resulting in improved patient outcomes.

Progenics Pharmaceuticals, Inc.
(PGNX) 4.54

777 Old Saw Mill River Road, Tarrytown, NY 10591

Progenics Pharmaceuticals is focusing on programs directed toward gastroenterology as well as the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus. In the area of HIV infection, the Company is developing the viral-entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immunotherapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA, and has a recombinant PSMA vaccine in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Proteome Systems

Locked Bag 2073, North Ryde, NSW, Australia 2113 6 Gill Street, Woburn, MA, 01801

Proteome Systems Limited is an Australian based biotechnology company which discovers and develops diagnostic and therapeutic products. The Company has extensive expertise in the discovery and development of protein biomarkers. Our lead programmes for biomarker discovery and development are Tuberculosis, Prostate Cancer and Huntington’s Disease. We have developed a rapid and quantitative diagnostic device platform known as DiagnostIQ, to facilitate the commercialisation of our biomarkers for diagnostic applications. An extensive patent portfolio of small molecule drug compounds entering clinical development with potential applications in several disease areas.

Reaction Biology Corporation

One Great Valley Parkway, Suite 8, Malvern, PA 19355

Reaction Biology Corp. ("RBC") was founded to pursue new economies in HTS and biochemical assays. RBC offers outsourced screening, profiling, and assay development, at lower cost than traditional outsourcing labs. RBC specializes in developing new nanoliter scale assaying methods. In addition, RBC performs NIH funded research on its DiscoveryDot™ microarray platform. DiscoveryDot™ uses a patent pending chemical archiving method, together with a unique spray deposition technique, to reduce compound volumes to the nanoliter scale.

Regeneron Pharmaceuticals Inc
(REGN) 24.67

777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. Regeneron has developed several proprietary platform technologies, which it has incorporated into a comprehensive discovery and development process designed to understand thoroughly the biology of specific disease states, discover potential therapeutic candidates, and evaluate these candidates in clinical trials.

Repligen Corporation
(RGEN) 3.42

41 Seyon St., Building 1, Suite 100, Waltham, MA 02453

Repligen Corporation is focused on the development of novel therapeutics for diseases that affect the central nervous system. A number of drug development programs are currently being conducted to evaluate our drug candidates in diseases such as bipolar disorder and neurodegeneration. We currently market two commercial products, Protein A and SecreFlo®.

Rosetta Genomics
(ROSG) 1.09

10 Plaut St., Rehovot, Israel, 76706 675 U.S Highway one, Suite: B119, North Brunswick, NJ 08902

Rosetta Genomics is the first commercial entity to focus on the emerging field of microRNA. The company is a leader in medical research and product development based on microRNA. Using our own proprietary bioinformatic technologies, researchers at Rosetta Genomics have identified the majority of human microRNA of which we are aware. From this unparalleled intellectual property platform, Rosetta is actively advancing multiple internal programs in microRNA diagnostic and therapeutic product development. We are also establishing licensing agreements and collaborative relationships with leading companies and research institutions working to develop microRNA-based products.

Savient Pharmaceuticals, Inc.
(SVNT) 14.68

One Tower Center, Fourteenth Floor, East Brunswick, NJ 08816

Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. We are concentrating on the development of Puricase®, our Phase 3 product candidate for treatment-failure gout. We currently distribute our branded product Oxandrin® (oxandrolone, USP) C III in the United States as an adjunctive therapy to combat weight loss resulting from chronic infection, extensive surgery and severe trauma. In addition, we also manufacture and supply an A-B rated authorized generic of oxandrolone tablets, (USP) C III, an Oxandrin brand equivalent, to a third party for subsequent sale and distribution.

Sentigen Biosciences, Inc.

3960 Broadway, New York, NY 10032-1543

Sentigen Biosciences’ primary focus is to apply its proprietary technologies to internal drug discovery and development initiatives targeting the largest class of receptors in the body, G Protein-Coupled Receptors (GPCRs). Sentigen Biosciences was founded on the belief that superior technologies to illuminate the signaling function of GPCRs and other molecular targets, as well as the development of molecular tools to manipulate these signaling processes could have widespread applications of enormous practical and commercial importance in drug discovery and other markets .

Sepracor, Inc.
(SEPR) 22.85

84 Waterford Drive Marlborough, MA 01752

Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing, and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Our drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on the treatment of respiratory and central nervous system disorders. We currently commercialize four proprietary products: LUNESTA® (eszopiclone); XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); XOPENEX® (levalbuterol HCl) Inhalation Solution; and BROVANATM (arformoterol tartrate) Inhalation Solution.

SeraCare LifeSciences, Inc.
*VENDOR*

375 West Street, West Bridgewater, MA 02379

SeraCare Life Sciences develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs, and additional research applications in the biotechnology, pharmaceutical, and diagnostic industries. SeraCare's offerings include plasma-based therapeutic products, diagnostic products and reagents, cell culture products, specialty plasmas, in vitro stabilizers, and clinically annotated DNA, RNA, serum, and tissue specimens ethically collected from consenting donors with a variety of patient conditions.

Siga Technologies Inc
(SIGA) 7.76

420 Lexington Avenue, Suite 408, New York, NY 10170 4575 SW Research Way, Suite 230, Corvallis, OR 97333

SIGA is committed to the discovery, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents.

Sirtris Pharmaceuticals
(SIRT) 0.00

790 Memorial Drive, Cambridge, MA 02139

Sirtris Pharmaceuticals™ is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic the beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins.

Symbollon Pharmaceuticals, Inc.
(SYMBA.OB) 0.03

37 Loring Drive, Framingham, MA 01702

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. We have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications. In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

Synvista Therapeutics, Inc.
(SYI) 1.32

221 West Grand Ave, Montvale, NJ 07645

*Changed name from Alteon in July 2007*
Synvista is developing new classes of drugs that have shown the potential to reverse or slow down diseases of aging and complications of diabetes. These compounds appear to have an impact on a fundamental pathological process caused by the progressive formation of protein-carbohydrate complexes called Advanced Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues and organs and have been shown to be a causative factor in many age-related diseases and diabetic complications. Synvista has created a library of novel classes of compounds targeting the A.G.E. pathway.

TEI Biosciences

7 Elkins Street, Boston, MA 02127

We are a private biomedical company developing, manufacturing, and marketing novel biological devices for the repair or replacement of failed human tissues and organs. Our history and expertise in regenerative medicine has led to the development of a leading patented platform technology, and, in turn, to a family of engineered devices (EBM) that we believe have biological and mechanical properties superior to competing devices. EBM is processed in a patented method that results in a strong, highly biocompatible collagen scaffold, approved by the FDA for use as a surgical mesh for a broad spectrum of tissue repair applications. EBM products include TissueMend®, Durepair®, Xenform™, PriMatrix™, and SurgiMend™. Our second platform technology is a family of proprietary cell-signaling complexes (Signal-plexes™), which we have shown in the lab to accelerate tissue repair. We have also demonstrated that they can direct the differentiation of stem cells, including those derived from adult human skin fibroblasts, to become a wide range of phenotypes dictated by the type of Signal-plex used. Signal-plexes may be incorporated into EBM or, alternatively, used independently as pharmacological agents for in-situ tissue or organ repair.

The Medicines Company
(MDCO) 11.88

8 Campus Drive, Parsippany, NJ 07054

The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax® (bivalirudin) for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators.

TheraQuest Biosciences

146 Medinah Drive, Blue Bell, PA 19422-3212

TheraQuest is a development stage pain management company with a diversified portfolio of products for the treatment of acute and chronic pain.

Therion Biologics Corporation

76 Rogers Street, Cambridge, MA 02142-1119

Therion Biologics Corporation develops therapeutic vaccines that aim to extend and improve the lives of cancer patients. The company has two lead product candidates: PANVAC-VF, entering a Phase III clinical trial for pancreatic cancer; and PROSTVAC®-VF in a Phase II clinical trial for prostate cancer. The company is applying its technology to develop its vaccine pipeline, including treatments for breast cancer, lung cancer, and the prevention of AIDS. Therion is also developing a vaccine for colon cancer with its strategic partner, Aventis Pasteur, Ltd. Through Therion's longstanding partnerships with the National Cancer Institute (NCI) and a network of renowned clinical institutions, over 700 patients in more than 30 clinical trials have been treated with Therion's vaccine candidates.

TranXenoGen

PO BOX 21, NORTHBORO, MA 01532

The Company is focused on developing new methods for manufacturing therapeutic proteins and a portfolio of products. Its product pipeline includes Anti-Neoplastic Urinary Protein ("ANUP") for the treatment of several types of cancer, Insulin and Human Serum Albumin ("HSA"). The Company believes that its technology platform will have multiple applications including the generation of transgenic chickens for the manufacture of high volume therapeutic proteins, animal models for the study of disease, and high throughput production of antibodies from genomic derived targets for product identification.

US Genomics

12 Gill Street, Suite 4700, Woburn, MA 01801

U.S. Genomics is pioneering tools to enable single molecule biology for the life sciences industry. The company develops and manufactures instruments and their associated reagents for researchers in academia, pharmaceutical and biotech companies, and contract research organizations. U.S. Genomics has introduced the Trilogy™2020 single molecule analyzer, a bench-top instrument, combining advances in microfluidics, optical engineering, and novel labeling strategies. The company's innovative technologies allow applications in genetics, functional genomics, biodefense, and diagnostics to be performed at the single molecule level.

Vaccinex

1895 Mt. Hope Avenue, Rochester, NY 14620

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies to treat a variety of serious diseases. The company's patented ACTIVMAb® technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Unique to this technology is the capability to recover fully functional human antibodies from libraries expressed in mammalian cells.

Verenium Corporation
(VRNM) 3.03

55 Cambridge Parkway Cambridge, MA 02142 4955 Directors Place, San Diego, CA 92121-1609

*Formed from merger of Diversa and Celunol in June 2007*
Verenium Corporation is developing new pathways to derive chemical building blocks from abundant, cellulosic biomass -- natural resources that are both renewable and widely distributed throughout the world. With its unique combination of expertise in enzymatic and fermentation technology, Verenium is developing new, lower-cost ways to produce these chemical building blocks and cost-effective, lower-impact substitutes. For example, Verenium’s fermentation process technology can be used to derive cheap sugars from common feedstocks for fuels production. Its DirectEvolution technology harnesses the power of enzymes to synthesize from living matter a wide range of novel compounds with unique properties tailored for specific applications. Verenium’s mission is to apply these technological capabilities to achieve industrial sustainability -- meeting the common needs of modern life from carbohydrates (the energy flows that are produced and stored in living biomass) rather than hydrocarbons (fossilized energy stocks that have been stored for countless millennia in the earth’s crust). Verenium’s innovative approach promises dramatic reductions in the carbon footprint of fuels production and other common industrial processes.

Vertex Pharmaceuticals, Inc.
(VRTX) 35.87

130 Waverly Street Cambridge, MA 02139 11010 Torreyana Road San Diego, CA 92121 88 Milton Park, Abingdon, Oxfordshire OX14 4RY UK

Vertex’s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline. The Company is leading the development of the HCV protease inhibitor, telaprevir (VX-950)

VIA Pharmaceuticals, Inc.
(VIAP.PK) 0.11

750 Battery St. Suite 330, San Francisco, CA 94111 101 College Road East, Princeton, NJ 08540

VIA Pharmaceuticals is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA’s lead product candidate, VIA-2291, is in two Phase II clinical studies in patients with acute coronary syndrome and patients with carotid artery disease. VIA’s drug development approach targets inflammation in the blood vessel (vascular) wall, an underlying cause of atherosclerosis and its complications. Atherosclerosis is a common cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. Plaque consists of inflammatory cells, cholesterol and cellular debris. Atherosclerosis, depending on the location of the artery it affects, may result in major adverse cardiovascular events (MACE), such as heart attack and stroke, which are the leading causes of death worldwide.

Viacell, Inc.
(VIAC) 0.00

245 First St, Cambridge, MA 02142

ViaCell is dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility.

Vion Pharmaceuticals Inc
(VIONQ.OB) 0.07

4 Science Park, New Haven, CT 06511

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® (VNP40101M) is underway in small cell lung cancer. Our second clinical-stage product, Triapine®, is being evaluated in several trials sponsored by the National Cancer Institute. Additional small molecule anticancer compounds are under development in preclinical studies.

ViroPharma, Inc.
(VPHM) 13.22

397 Eagleview Boulevard, Exton, PA 19341

We are a pharmaceutical company focused on the development and commercialization of important medicines to address serious diseases treated by physician specialists, in areas including hospital settings, transplant medicine and gastroenterology. Our marketed product, VANCOCIN® CAPSULES , is a potent oral antibiotic used by our target physician specialists, internists and gastroenterologists primarily in hospital settings, to treat two significant bacterial infections of the lower digestive tract: antibiotic-associated pseudomembranous colitis (PMC) and staphylococcal enterocolitis. Further, we are developing two promising core clinical opportunities, maribavir for prevention of cytomegalovirus infection, and our our hepatitis C compound, HCV-796. Finally, we have intranasal pleconaril, a financial value driver for ViroPharma now in the hands of Schering-Plough.

Wellgen, Inc.

675 US Highway One, North Brunswick, NJ 08902

The company has identified several bioactive compounds found in food that alter the expression of genes associated with inflammation, arthritis, obesity and cancer. We have exclusive license to over twenty patents in various stages of progress, and devote significant resources to protecting and expanding our intellectual portfolio. We are conducting human pilot studies on several of our bioactive products. With offices in the Center for Advanced Food Technology at Rutgers University, we are uniquely positioned to participate in collaborative university research programs. WellGen is discovering and developing nutrigenomics ingredients that will provide health benefits to consumers and satisfy significant market needs. We will sell our proprietary products as nutritional ingredients with scientifically validated benefits to the major markets that include functional foods, dietary supplements, pet foods, cosmeceuticals and drugs.

Xenogen Biosciences
*SERVICE*

68 Elm Street, Hopkinton, MA 01748 5 Cedar Brook Drive Cranbury, NJ 08512

Xenogen Biosciences, a subsidiary of Xenogen Corporation, has a long and respected track record in the design and production of genetic modifications in animal models using pronuclear microinjection and/or gene knockout/knockin techniques, and breeding services. To date, Xenogen has produced over 8,000 unique transgenic mice and rats from over 2,500 transgene constructs. More than 97% of all gene constructs have successfully produced transgenic mice and rats, or gene knockout lines. In sum, Xenogen offers the biomedical community a long-proven and integrated array of genetically-modified animal creation capabilities, as well as a comprehensive phenotyping platform to characterize such animal lines, and an in vivo compound profiling program to characterize the effects of compounds in rodent models.

Xenomics, Inc.
(TROV.PK) 0.35

420 Lexington Avenue, Suite 1701, New York, NY 10170 One Deer Park Drive, Suite F, Monmouth Junction, NJ 08852

Xenomics, Inc. is the developer of next-generation molecular diagnostics products that address important health problems worldwide. Our mission is to apply our proprietary transrenal DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics that replace outdated blood, sputum, and tissue testing technologies many of which are not sufficiently sensitive and specific, and are often hazardous, and difficult to automate. The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets including infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, human forensics, and biodefense. Xenomics has made continuing progress in its clinical studies in infectious disease testing, particularly in the field of TB detection and therapeutic monitoring, HIV proviral DNA detection, and detection of early cancer genetic markers.